サンプル依頼リスト カート
  • English
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1747036

日本の血友病市場レポート：タイプ別、治療別、治療法別、地域別、2025～2033年

Japan Hemophilia Market Report by Type (Hemophilia A, Hemophilia B, Hemophilia C, and Others), Treatment (On-Demand, Prophylaxis), Therapy (Replacement Therapy, ITI Therapy, Gene Therapy), and Region 2025-2033

出版日
発行
IMARC
ページ情報
英文 117 Pages
納期
5～7営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.80円
日本の血友病市場レポート：タイプ別、治療別、治療法別、地域別、2025～2033年
出版日: 2025年06月02日
発行: IMARC
ページ情報: 英文 117 Pages
納期: 5～7営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

日本の血友病市場規模は2024年に8億4,600万米ドルに達しました。今後、IMARC Groupは、同市場が2033年までに15億8,900万米ドルに達し、2025～2033年にかけて7.3%の成長率（CAGR）を示すと予測しています。日本の強固なヘルスケアインフラ、早期診断と効果的な管理への注目の高まり、研究開発（R&D）活動の活発化、血友病ケアの急速な進歩、製薬会社とハイテク企業間の企業提携の拡大は、市場を牽引する主要因のいくつかです。

本レポートで扱う主要質問

  • 日本の血友病市場はこれまでどのように推移し、今後どのように推移するのか？
  • COVID-19が日本の血友病市場に与えた影響は？
  • 日本の血友病市場のタイプ別区分は？
  • 日本の血友病市場の治療別区分は？
  • 日本の血友病市場の治療法別区分は？
  • 日本の血友病市場のバリューチェーンにおける各段階とは？
  • 日本の血友病における主要な促進要因と課題は何か？
  • 日本の血友病市場の構造と主要参入企業は？
  • 日本の血友病市場における競合の程度は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査の目的
  • ステークホルダー
  • データソース
  • 市場推定
  • 調査手法

第3章 エグゼクティブサマリー

第4章 日本の血友病市場-イントロダクション

  • 概要
  • 市場力学
  • 産業動向
  • 競合情報

第5章 日本の血友病市場情勢

  • 過去と現在の市場動向（2019～2024年）
  • 市場予測（2025～2033年）

第6章 日本の血友病市場-タイプ別内訳

  • 血友病A
  • 血友病B
  • 血友病C
  • その他

第7章 日本の血友病市場-治療別内訳

  • オンデマンド
  • 予防

第8章 日本の血友病市場-治療法別内訳

  • 補充療法
  • ITI療法
  • 遺伝子治療

第9章 日本の血友病市場-競合情勢

  • 概要
  • 市場構造
  • 市場企業のポジショニング
  • 主要成功戦略
  • 競合ダッシュボード
  • 企業評価象限

第10章 主要企業のプロファイル

第11章 日本の血友病市場-産業分析

  • 促進要因・抑制要因・機会
  • ポーターのファイブフォース分析
  • バリューチェーン分析

第12章 付録

目次
Product Code: SR112025A18960

The Japan hemophilia market size reached USD 846.0 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 1,589.0 Million by 2033, exhibiting a growth rate (CAGR) of 7.3% during 2025-2033. The robust healthcare infrastructure in Japan, increasing focus on early diagnosis and effective management, rising research and development (R&D) activities, rapid advancements in hemophilia care, and the growing corporate partnerships between pharmaceutical companies and tech firms represent some of the key factors driving the market.

Hemophilia refers to a rare genetic disorder characterized by the inability of the blood to clot properly, leading to prolonged bleeding. It is caused by the deficiency or absence of specific clotting proteins, such as Factor VIII or Factor IX, in the blood. It primarily occurs in two forms, such as Hemophilia A and Hemophilia B, distinguished by the specific clotting factor that is either reduced or missing. Hemophilia exhibits various symptoms such as frequent nosebleeds, easy bruising, joint pain, and severe bleeding from minor injuries. It is diagnosed through physical examination, medical history evaluation, genetic testing, inhibitor testing, and various laboratory tests, such as clotting factor assays. Hemophilia is treated using multiple methods, such as replacement therapy, prophylactic treatment, gene therapy, clot-promoting medications, pain management strategies, and supportive care. They aid in preventing bleeding episodes, improving quality of life, reducing pain, and minimizing joint damage.

Japan Hemophilia Market Trends:

The robust healthcare infrastructure in Japan, facilitating easier access to diagnostics and treatment for hemophilia patients, is one of the major factors contributing to the market growth. Moreover, the increasing focus on early diagnosis and effective management of the condition due to the high standard of healthcare services in the country is positively impacting the market growth. Additionally, the rising research and development (R&D) activities, backed by public and private investments, are providing a thrust to the market growth. In line with this, rapid advancements in hemophilia care, such as the development of extended half-life clotting factors and exploration of gene therapy options, are creating a positive outlook for the market growth. Furthermore, the increasing life expectancy of the population in Japan, requiring the need for long-term management of chronic conditions like hemophilia, is providing a thrust to the market growth. In addition to this, the implementation of various government grants and incentives for research projects focused on rare diseases is acting as a growth-inducing factor. Along with this, rapid advancements such as telemedicine, which make it easier for patients to consult with specialists, especially for those living in remote areas, are boosting the market growth. Besides this, the increasing prevalence of wearable technologies for health monitoring that are customized to monitor specific variables related to hemophilia is catalyzing the market growth. Apart from this, the widespread adoption of international treatment guidelines and protocols in Japan that help standardize care and make treatment more predictable and effective is bolstering the market growth. In line with this, the growing government aid in insurance approvals for certain kinds of treatments and medications that were earlier difficult to access is fostering the market growth.

Japan Hemophilia Market Segmentation:

Type Insights:

  • Hemophilia A
  • Hemophilia B
  • Hemophilia C
  • Others

Treatment Insights:

  • On-Demand
  • Prophylaxis

Therapy Insights:

  • Replacement Therapy
  • ITI Therapy
  • Gene Therapy

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Key Questions Answered in This Report:

  • How has the Japan hemophilia market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the Japan hemophilia market?
  • What is the breakup of the Japan hemophilia market on the basis of type?
  • What is the breakup of the Japan hemophilia market on the basis of treatment?
  • What is the breakup of the Japan hemophilia market on the basis of therapy?
  • What are the various stages in the value chain of the Japan hemophilia market?
  • What are the key driving factors and challenges in the Japan hemophilia?
  • What is the structure of the Japan hemophilia market and who are the key players?
  • What is the degree of competition in the Japan hemophilia market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Japan Hemophilia Market - Introduction

  • 4.1 Overview
  • 4.2 Market Dynamics
  • 4.3 Industry Trends
  • 4.4 Competitive Intelligence

5 Japan Hemophilia Market Landscape

  • 5.1 Historical and Current Market Trends (2019-2024)
  • 5.2 Market Forecast (2025-2033)

6 Japan Hemophilia Market - Breakup by Type

  • 6.1 Hemophilia A
    • 6.1.1 Overview
    • 6.1.2 Historical and Current Market Trends (2019-2024)
    • 6.1.3 Market Forecast (2025-2033)
  • 6.2 Hemophilia B
    • 6.2.1 Overview
    • 6.2.2 Historical and Current Market Trends (2019-2024)
    • 6.2.3 Market Forecast (2025-2033)
  • 6.3 Hemophilia C
    • 6.3.1 Overview
    • 6.3.2 Historical and Current Market Trends (2019-2024)
    • 6.3.3 Market Forecast (2025-2033)
  • 6.4 Others
    • 6.4.1 Historical and Current Market Trends (2019-2024)
    • 6.4.2 Market Forecast (2025-2033)

7 Japan Hemophilia Market - Breakup by Treatment

  • 7.1 On-Demand
    • 7.1.1 Overview
    • 7.1.2 Historical and Current Market Trends (2019-2024)
    • 7.1.3 Market Forecast (2025-2033)
  • 7.2 Prophylaxis
    • 7.2.1 Overview
    • 7.2.2 Historical and Current Market Trends (2019-2024)
    • 7.2.3 Market Forecast (2025-2033)

8 Japan Hemophilia Market - Breakup by Therapy

  • 8.1 Replacement Therapy
    • 8.1.1 Overview
    • 8.1.2 Historical and Current Market Trends (2019-2024)
    • 8.1.3 Market Forecast (2025-2033)
  • 8.2 ITI Therapy
    • 8.2.1 Overview
    • 8.2.2 Historical and Current Market Trends (2019-2024)
    • 8.2.3 Market Forecast (2025-2033)
  • 8.3 Gene Therapy
    • 8.3.1 Overview
    • 8.3.2 Historical and Current Market Trends (2019-2024)
    • 8.3.3 Market Forecast (2025-2033)

9 Japan Hemophilia Market - Competitive Landscape

  • 9.1 Overview
  • 9.2 Market Structure
  • 9.3 Market Player Positioning
  • 9.4 Top Winning Strategies
  • 9.5 Competitive Dashboard
  • 9.6 Company Evaluation Quadrant

10 Profiles of Key Players

  • 10.1 Company A
    • 10.1.1 Business Overview
    • 10.1.2 Service Offered
    • 10.1.3 Business Strategies
    • 10.1.4 SWOT Analysis
    • 10.1.5 Major News and Events
  • 10.2 Company B
    • 10.2.1 Business Overview
    • 10.2.2 Service Offered
    • 10.2.3 Business Strategies
    • 10.2.4 SWOT Analysis
    • 10.2.5 Major News and Events
  • 10.3 Company C
    • 10.3.1 Business Overview
    • 10.3.2 Service Offered
    • 10.3.3 Business Strategies
    • 10.3.4 SWOT Analysis
    • 10.3.5 Major News and Events
  • 10.4 Company D
    • 10.4.1 Business Overview
    • 10.4.2 Service Offered
    • 10.4.3 Business Strategies
    • 10.4.4 SWOT Analysis
    • 10.4.5 Major News and Events
  • 10.5 Company E
    • 10.5.1 Business Overview
    • 10.5.2 Service Offered
    • 10.5.3 Business Strategies
    • 10.5.4 SWOT Analysis
    • 10.5.5 Major News and Events

11 Japan Hemophilia Market - Industry Analysis

  • 11.1 Drivers, Restraints, and Opportunities
    • 11.1.1 Overview
    • 11.1.2 Drivers
    • 11.1.3 Restraints
    • 11.1.4 Opportunities
  • 11.2 Porters Five Forces Analysis
    • 11.2.1 Overview
    • 11.2.2 Bargaining Power of Buyers
    • 11.2.3 Bargaining Power of Suppliers
    • 11.2.4 Degree of Competition
    • 11.2.5 Threat of New Entrants
    • 11.2.6 Threat of Substitutes
  • 11.3 Value Chain Analysis

12 Appendix